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Background: Initial glitches and unexpected inconsistencies are unavoidable in the early stage of a large, multi-
centre trial. Adaptive modifications of the trial’s protocol and operational procedures to ensure its smooth running
are therefore imperative. We started a large pragmatic, multi-centre, assessor-blinded, 25-week trial to investigate
the optimal first- and second-line treatments for untreated episodes of nonpsychotic major depression in 2010
[Strategic Use of New generation antidepressants for Depression, abbreviated SUN(^_^)D] and would like to herein
report an examination of the trial’s feasibility and adherence among the first 100 participants.
Methods: We examined the participants’ characteristics, the treatments that were allocated and received during
each step of the trial, and the quality of the outcome assessments among the first 100 patients enrolled in the SUN
(^_^)D trial.
Results: Of the 2,743 first-visit patients who visited the two collaborating centres between December 2010 and July
2011, 382 were judged as potentially eligible, and 100 of these patients provided written informed consent. These
patients represented the whole spectrum of mild to very severe depression. Of the 93 patients who had reached
Week 3 of the study by the end of July 2011, one withdrew consent for both the treatment and the assessment,
and eight withdrew consent for the treatment only. Altogether, the primary outcomes were successfully assessed in
90 (96.8%) of the patients at Week 3. Of the 72 patients who had reached Week 9, three withdrew consent for the
treatment, but 70 were successfully interviewed (97.2%). Of the 32 patients who had reached Week 25, 29 (90.5%)
were successfully followed up. The inter-rater reliability of the assessments of the primary outcomes was nearly
perfect and their successful blinding was confirmed. Minor modifications and clarifications to the protocol were
deemed necessary.
Discussion: Given the satisfactory feasibility and adherence to the study protocol and the minor modifications that
were necessary, we conclude that the data obtained from the first 100 patients can be safely included in the main
study. We now intend to accelerate the study by recruiting more collaborating centres and clinics/hospitals.
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A randomised clinical trial can only be started after its proto-
col and operational procedures have been fixed and written
down in detail. Like any industrial product, however, some
malfunctioning glitches and unexpected inconsistencies are
unavoidable, especially during the early stages. Adaptively
modifying the protocol and operational procedures to ensure
the study’s smooth running is therefore imperative.
No guidelines exist, however, on how to implement this
crucial step in the conduct of a clinical trial. One often-used
method is to run a pilot study, separately from and before
the formal study [1,2]. A drawback to this approach is that
the data from this sample cannot in principle be merged
into the full data set, especially if only limited aspects of the
whole protocol are to be implemented and evaluated in the
pilot study or if the randomisation is broken. Moreover, lim-
iting the scope of the pilot study to avoid wasting valuable
patient resources may ironically mean that all the study pro-
cedures cannot be fully tested in the pilot phase and that
the same problem of initial adjustments may have to be
worked through de novo only after the full-scale formal
study has been initiated.
The Strategic Use of New generation antidepressants for
Depression, or SUN(^_^)D for short, is a large pragmatic
multi-centre, assessor-blinded, parallel-group trial to exam-
ine the optimal first- and second-line treatments of hereto-
fore untreated episodes of nonpsychotic unipolar major
depression [3]. It first compares the rapid titration strategy
up to the maximum tolerable dosage versus the titration up
to the minimum effective dosage of a selective serotonin-
reuptake inhibitor (SSRI) antidepressant in the first-line
treatment of depression in a cluster-randomised design.
When the first-line treatment fails to achieve remission, it
then attempts to compare three second-line treatment strat-
egies, namely to augment the SSRI with a noradrenergic
and specific serotonergic antidepressant (NaSSA), to switch
from SSRI to NaSSA, or to continue several more weeks
with SSRI, in an individually randomised comparison. The
study will enrol 2,000 adult patients with untreated major
depressive episodes seeking treatment at psychiatric clinics
and hospitals at a number of regional centres from all over
Japan.
In this large pragmatic psychiatric trial, we opted to in-
clude the feasibility examination in the main study itself.
Namely, we decided to implement the whole study proced-
ure from the very beginning, but at a limited number of re-
gional centres, to examine the feasibility of the original
protocol as well as the adherence of both the patients and
the doctors to the protocol, and to modify, if necessary, the
protocol and operational procedures as the first patients
are enrolled in the study [3]. The current report describes
the results of the feasibility and adherence examination
among our first 100 patients, and details the required
amendments to the SUN(^_^)D study protocol.Methods
Ethics
The original study protocol was approved by the Institu-
tional Review Board (IRB) at Nagoya City University
Hospital in April 2010 by the Ethics Committee at Kyoto
University Graduate School of Medicine in August 2010
and by the Ethics Committee at Kochi University Medical
School in October 2010. The pilot phase of the SUN(^_^)D
started its recruitment at two regional centres in Nagoya
and Kochi on 6 December 2010, with the centre in Kyoto
serving as the central office. Eligible patients provided writ-
ten informed consent after receiving a full disclosure and
explanation of the purpose and procedures of the study.
This trial has been registered at ClinicalTrials.gov as
NCT01109693.
Procedures
The full details of the procedures of the study are given in
the published protocol [3] and we briefly present the overall
flow of the trial, the participants’ eligibility criteria and the
outcome measures here.
Figure 1 presents the overall procedure of the trial. The
participants’ eligibility criteria are listed in Table 1. We
chose sertraline as the first-line SSRI treatment because it
was found to offer the best balance between efficacy and tol-
erability among the currently marketed anti-depressant
drugs in Japan according to a recent multiple-treatments
meta-analysis of 12 new-generation antidepressants [4]. The
optimum titration strategy, however, has never been system-
atically examined in the literature. In step I, therefore, eli-
gible and consenting patients will either receive sertraline
titrated up to 50 mg/day or up to 100 mg/day unless pro-
hibited by adverse effects for 3 weeks. We employed the
cluster randomisation design for step I, i.e. the participating
sites were randomised either to 50 mg/or 100 mg/d arms.
When sertraline fails as a first-line treatment to achieve
remission, one natural choice is to switch to the antidepres-
sant found to be the most efficacious, albeit with reduced
acceptability, in the same meta-analysis, namely mirtaza-
pine [4]. Because this NaSSA has a different neurochemical
profile than SSRI and has been found to work in synergy
when combined with SSRI in a number of trials [5-7], an-
other option is to augment SSRI with mirtazapine. These
two second-line options are to be compared with continu-
ing with sertraline for 6 more weeks in step II. If the
patients remit after receiving the first-line treatment, they
are to continue with the first-line treatment in step II.
Step III is a 16-week extension of steps I and II, in which
the doctors and the patients are free to continue their step
II treatments or to choose whatever treatments they deem
appropriate. This stage represents the important continu-
ation phase in the treatment of major depression, because
almost every patient is advised to receive this continuation
























Figure 1 Flow diagram of the trial.
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tinued to sustain remission.
The primary outcome measures include the Patient Health
Questionnaire-9 (PHQ-9) [9] and the Frequency, Intensity
and Burden of Side Effects Rating (FIBSER), as assessed by
the central raters at weeks 1, 3, 9 and 25. The assessment is
conducted via telephone while the assessors are blinded to
the treatment status of the patients. The inter- and intra-
rater reliability of the primary outcome measures was exam-
ined by having all six raters re-assess the audio recordings of
the 20 telephone interviews. The secondary outcomes
included the Beck Depression Inventory-II [10], rated by the
patients themselves.
As we had declared in the protocol [3], the analyses of the
pilot phase were to be performed without knowledge of the
allocated treatments and would not involve any statistical
comparison between randomised arms. Unless a major
change in the study protocol was required, the participants
in the pilot phase would therefore be eligible for inclusion in
the main study.
Analyses
In this study the focus was placed on how feasible the ori-
ginal protocol was and how adherent the doctors and the
patients were to steps I through III of the study. All the data
had been provided to the researchers from the data centre
without any information linking the treatment allocationsand assessment results. We first reported the demographic
and clinical characteristics of the screened patients as well as
the finally enrolled patients to examine the efficiency of our
recruitment procedure as well as to ascertain whether the
intended types of patients had been recruited into the study.
We then examined whether the randomisation had been
successful, if the treatments as stipulated in the protocol had
been adhered to and if the assessments had been made with
satisfactory follow-up rates in each step of the trial.
The quality of the assessments is of paramount import-
ance in a trial. We therefore examined the reliability of our
primary outcomes and whether the blinding had been suc-
cessfully implemented in the study.
Finally, we also reported the important safety aspects
among our first 100 patients.
Results
Participating sites
Two regional centres participated in the pilot phase of the
SUN(^_^)D. One regional centre consisted of one general
hospital and five private psychiatric clinics, while the other
centre included four hospitals and two private psychiatric
clinics.
Participants
Altogether 2,743 first-visit patients visited the participating
sites between 6 December 2010 and 31 July 2011. After
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
(1) The participant fulfils criteria for non-psychotic
unipolar major depressive episode
(DSM-IV) within 1 month before starting sertraline
1) Having taken antidepressants, mood stabilizers
(lithium, valproate, carbamazepine, lamotrigine),
antipsychotics, psychostimulants
(methylphenidate, pemoline, atomoxetine),
electroconvulsive therapy, rTMS, light therapy,
or depression-specific psychotherapies
(cognitive-behaviour therapy, interpersonal therapy)
within 1 month before starting sertraline
(2) Age between 25 and 75 on the day when
sertraline is started
(2) History of schizophrenia, schizoaffective disorder or bipolar disorder
(DSM-IV) as judged by treating physician
(3) The major depressive episode is the focus of the
treatment and the treating physician has judged
sertraline to be its appropriate first-line drug
(3) Current dementia, borderline personality disorder,
eating disorder or substance dependence
(DSM-IV) as judged by treating physician
(4) Tolerability to sertaline has been ascertained
after 3–16 days of treatment with sertraline
25 mg/day
(4) Physical diseases that may contraindicate treatment with
sertraline or mirtazapine
(5) The participant is able to understand
and sign written informed consent
(5) Allergy to sertraline or mirtazapine
(6) The participant is available on the phone for
assessment of symptoms and side effects
(6) Terminal physical diseases
(7) Women who are pregnant or breastfeeding
(if there is a possibility of getting pregnant within 6 months of trial entry,
participation is allowed only after providing signed consent to avoid
pregnancy during the trial period)
(8) Imminent high risk of suicide as judged by treating physician
(9) Needing non-voluntary hospitalisation
(10) High probability of changing hospital due to relocation, etc.,
within 6 months of trial entry
(11) Cohabiting family members of research staff members of the trial
(12) Inability to understand written Japanese
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diagnosis with the help of the semi-structured interview
PRIME-MD [9], 382 patients were judged to have suffered
from a major depressive episode during the past month and
to have had no treatment. One hundred of these patients
were subsequently judged to meet all the eligibility criteria,
provided written informed consent after full explanation of
the purpose and procedures of the study, and were enrolled
in the study (Figure 2).
Figure 3 depicts the monthly recruitment of the partici-
pants for the first 8 months of the study. On average, 12.5
patients were enrolled per month (Figure 4).
Table 2 describes the basic demographic characteristics of
these participants. The subjects were approximately equally
divided into both sexes and represented the whole age range
as specified in the protocol, with a peak age occurring in the
5th decade. Slightly more than half of the patients had
received education at a college or university level or beyond.
About half the subjects were employed at the time of their
entry into the study, but about a third were on sick leave.
Table 3 gives the clinical characteristics of the participants.
The average age of the participants at the onset of the de-
pressive disorder was in their 30s, some 5 years earlier thantheir age at first visit. For half of the cohort, the index epi-
sode was their first major depressive episode, but the others
had had up to four previous episodes. The median length of
the episode before the hospital visit was 2.5 months, with a
range of between 0.5 to 120 months. The participants’ aver-
age depression scores were 18.9 for the PHQ-9 and 33.0 for
the BDI-II, but the score varied between 8 to 27 and 14 to
52, respectively, thus representing the whole spectrum of
mild to very severe depression [11].
Adherence to the protocol in step I
Treatment allocation at the beginning of step I
Of the 100 initial participants, 16 were recruited at the five
sites allocated to the sertraline 50 mg/day arm and the
remaining 84 were recruited at seven sites allocated to the
sertraline 100 mg/day arm. This imbalance in the number of
recruited patients was due to one site that recruited the lar-
gest number of patients.
Treatment received by the end of step I
Of the 100 patients who had provided their written informed
consent at week 1 by the end of July (the observation period
for this feasibility study), 93 would have reached week 3
2743 first-visit patients were screened
678 patients with major depressive 
episode in past month
382 non-treated patients with MDE in 
past month
100 gave informed consent
93 have reached Week 3
90 were assessed at Week 3 (96.8%)
72 have reached Week 9
70 were assessed at Week 9 (97.2%)
32 have reached Week 25
29 were assessed at Week 25 (90.6%)
3 were not 
available
2 were not 
available
3 were not 
available
Figure 2 Flowchart of the participants as of the end of July
2011.
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ments that these patients received in step I.
Of these 93 patients, 16 were in the sertraline 50 mg/day
arm and 77 were in the sertraline 100 mg/day arm. None of
the 16 patients allocated to the sertraline 50 mg/day arm
withdrew their consent and all these patients had reached
the designated dosage by week 3.
Of the 77 participants allocated to the 100 mg/day arm,
one withdrew consent to both the protocol treatment and to
undergoing further assessments, and was therefore dropped
from the study. Eight additional patients withdrew consent
to the protocol treatment by week 3, but consented to fur-
ther assessments at weeks 3, 9 and 25: one patient had
improved considerably and decided to stop the medication,
one patient decided to stop the drug because of side effects,
one patient was hospitalised because of depressive stupor,
one patient started working and could not come to the clinic
at the appointed times, two patients moved, and two patients
withdrew consent for unknown reasons. Of the 68 patients
allocated to the sertraline 100 mg/day arm and whose con-
sent to the treatment remained valid, 10 did not reach the
intended dosage by week 3 and were only receiving 75 mg/
day.
None of the participants received the prohibited concomi-
tant treatments during step I.
Assessment at the end of step I
Regardless of the treatments received, 93 patients should have
received their week 3 assessments during the present study’s
observation period. Unfortunately, two of the eight patients
who withdrew their consent to the protocol treatment but still
agreed to further assessments were unreachable at week 3.
Thus, altogether three patients (one who withdrew consent to
treatment and to further assessment, and two who withdrew
consent to treatment but not to assessment) did not undergo
PHQ-9 and FIBSER assessments at week 3. The follow-up
rate was 96.8% (90/93).
Adherence to the protocol in step II
Treatment allocation at the beginning of step II
Of the 93 patients who reached week 3 by end of July, 9 had
withdrawn consent to treatment and 84 patients could there-
fore be randomised at week 3. Seven of these patients scored
4 or less on the PHQ-9 at week 3 and were therefore pre-
scribed the same antidepressant in step II as in Step I. The
nine patients who had withdrawn their consent to treatment
received treatments of their and their doctors’ choice.
Seventy-seven patients were then randomised in a 1:1:1
manner to continue sertraline, to receive mirtazapine aug-
mentation, or to switch from sertraline to mirtazapine. The
allocated numbers of patients were 26, 24 and 27, respectively,
and the randomisation procedure seemed to be result in








Dec Jan Feb Mar Arp May Jun Jul
Monthly
Cumulative
Figure 3 Monthly recruitment of the participants.
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Of the 77 patients randomised at week 3, 62 would have
reached week 9 by the end of July (the observation period for
this feasibility study).
Twenty-two had been allocated to continue sertraline and
should have reached week 9; only one of them dropped out
of the treatment prematurely. Nineteen had been allocated
to receive mirtazapine augmentation of sertraline and should
have reached week 9; all of them received the protocol treat-
ment (i.e. 50–100 mg/day of sertraline plus 7.5 to 45 mg/day
of mirtazapine). Twenty-one patients had been allocated to
the switching-to-mirtazapine group; two of them stoppedPHQ-9 n=100 n=100 n=90









Week 0 Week 1 Week 3
Figure 4 Average course of depression severity of the entire cohort.the treatment prematurely but all the others had been suc-
cessfully switched to mirtazapine 15–45 mg/day. None of
the patients received the prohibited concomitant treatments
during step II.
Assessment at the end of step II
Of the original 100 patients recruited into the study, 72
should have reached their week 9 assessments by the end of
July. In step II three patients dropped out from the protocol
treatment but none of them withdrew their consent to fur-
ther assessment (the one participant who withdrew consent
to both the treatment and the assessments in step I had notn=70 n=32
n=64 n=27
Week 9 Week 25
PHQ9
BDI-II
Table 2 Demographic characteristics of the first 100
patients in SUN(^_^)D
Age, years 42.4 (SD=12.7, range: 25–75)
Sex 56 women/44 men
Education 8 with junior high school or equivalent
30 with senior high school or equivalent
53 with junior college or university level
9 with above university level
Job 36 employed full-time
8 employed part-time
28 on sick leave
16 housewives
2 students
10 with no employment
Marriage 34 single, never married
13 single, divorced or separated
2 single, deceased
51 married
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tient who had been hospitalised in step I and another who
had been allocated to the continuation of sertraline group inTable 3 Clinical characteristics of the first 100 patients in SUN




Length of current episode,
months
Out- or inpatient status at time of entry into the study
PHQ-9
BDI-II
Physical conditionsstep II but stopped treatment prematurely despite medical
advice was unreachable at week 9. The follow-up rate was
therefore 70/72, or 97.2%.
Adherence to the protocol in step III
Treatments received in step III
This feasibility and adherence study did not closely exam-
ine the contents of the treatments provided to the patients
in step III because, according to our protocol, there were
no prohibited co-interventions for this period, and the ad-
herence to protocol treatments presented no concern in
this step. The contents of the treatments provided were
recorded in the data set; at end of week 25, 53% of the
patients reported that they were continuing to receive the
protocol treatment assigned to them in step II.
Assessment at the end of step III
Of the original 100 patients recruited into the study, 32
patients should have had their week 25 assessments by
the end of July. So far we have been able to follow-up 29
of these patients (90.6%).
Primary outcomes
Inter- and intra-rater reliability of the primary outcomes
Table 4 shows the ANOVA intra-class correlation coeffi-
cients for the individual items of the PHQ-9 and the(^_^)D
37.3 (SD=14.0, range: 10 to 75)
50 with no episode
32 with one episode
10 with two episodes
2 with three episodes
6 with four episodes
6.0 (SD= 13.6, median = 2.5, range: 0.5 to 120)
100 outpatients
18.9 (SD= 3.7, range: 8 to 27) at baseline
16.0 (SD= 4.5, range: 7 to 25) at week 1
33.0 (SD= 8.4, range: 14 to 52) at baseline
28.1 (SD= 9.8, range: 6 to 54) at week 1
66 with no physical comorbidity
6 with hypertension
5 with diabetes mellitus
4 with hypercholesterolemia
2 each with hyperthyroidism, glaucoma, goitre, headache
(including migraine) or arthritis
1 each with hepatitis C, Meniere’s disease, asthma, haemorrhoids,
kidney stone, esophagitis, arrhythmia, or collagen disease
Table 4 Inter-rater reliability for PHQ-9 and FIBSER
PHQ-9 Item 1 (anhedonia) 0.953 (0.915 to 0.978)
Item 2 (depressed mood) 1.000 (−)
Item 3 (sleep problem) 1.000 (−)
Item 4 (anergia) 1.000 (−)
Item 5 (appetite problem) 0.992 (0.985 to 0.996)
Item 6 (guilt feelings) 1.000 (−)
Item 7 (concentration problem) 0.984 (0.970 to 0.993)
Item 8 (psychomotor symptoms) 1.000 (−)
Item 9 (suicidal wishes) 1.000 (−)
Total score 0.998 (0.996 to 0.999)
FIBSER Item 1 (adherence) 1.000 (−)
Item 2 (frequency of side effects) 1.000 (−)
Item 3 (strength of side effects) 1.000 (−)
Item 4 (burden of side effects) 0.996 (0.993 to 0.998)
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re-assessments made by six interviewers of ten audio
recordings of telephone interviews. The inter-rater reli-
ability among the six raters was perfect to nearly perfect.
The intra-rater (test-retest) reliability of the telephone
assessments, that is the agreement between the inter-
viewer’s ratings during the telephone interview and those
made by the same interviewer when he/she listened to
his/her own recordings 1 to 2 weeks later, was perfect
for all the items.
Assessors’ blindness to allocated treatments
The assessors’ blindness to the allocated treatment was
evaluated by tabulating their guessed treatments and the
actually allocated treatments.
Table 5 presents such agreement for step I allocations
and Table 6 presents the same data for the step II alloca-
tions. Because the assessors were blinded to the timing
of the assessments, they sometimes made mixed guesses
for both step I and step II. The agreement for the cor-
rect versus incorrect guesses for the step I treatmentsTable 5 Examination of assessor blindness: Treatment
guesses for week 3 assessments
Guess Actual
50 mg/day 100 mg/day
50 mg/day at week 3 5 31
100 mg/day at week 3 8 23
Continue sertraline at week 9 2 15
Augment with mirtazapine at week 9 - 4
Switch to mirtazapine at week 9 - 1
Remitted at week 9 1 -was a kappa of −0.19 (95% CI: -0.34 to −0.04) and that
for the step II treatments was a kappa of −0.04 (−0.14 to
0.06).
Overall outcomes
Figure 3 presents the overall outcomes of our cohort as
a group, undivided for the treatments allocations.
The number of remitters (PHQ-9 =<4) were 10, 21
and 16 at week 3, 9 and 25, respectively. These figures
correspond to 10.8% (10/93), 29.2% (21/72) and 50.0%
(16/32) of the intention-to-treat sample, respectively.
Adverse events and change in diagnoses
No serious adverse event has been reported among the
first 100 patients in the first 8 months of the SUN(^_^)
D trial.
Suicidality was assessed according to the Columbia
Classification Algorithm of Suicide Assessment (C-CASA)
[12] at week 9 and at week 25 retrospectively by the treat-
ing psychiatrists. No case of a completed suicide, suicide at-
tempt or preparatory act toward imminent suicidal
behaviour was reported. Two patients expressed strong sui-
cidal ideation to the doctor and/or the families.
One patient presented with depressive stupor and was
hospitalised during step I. One patient presented with a
hypomanic episode during step II. No other changes in
the diagnoses have been reported.
Modifications to the original protocol and procedures
Through the initial pilot phase of SUN(^_^)D, only the
following minor modifications to the protocol and the
operational procedures were necessary.
1) We added repetitive transcranial magnetic
stimulation (rTMS), light therapy and lamotrigine as
prohibited treatments both before entry to the trial
and in steps I and II. We had overlooked rTMS and
light therapy in the original protocol. LamotrigineTable 6 Examination of assessor blindness: Treatment









50 mg/day at week 3 1 2 3 2
100 mg/day at week 39 6 5 -
Continue sertraline at
week 9
6 8 8 1
Augment with
mirtazapine at week 9
4 2 4 -
Switch to mirtazapine
at week 9
- - 1 -
Remitted at week 9 1 1 - 1
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study was begun.
2) We explicated the eligibility criteria by adding, “The
major depressive episode is the focus of the
treatment” because we encountered patients with
major depressive episodes comorbid with anxiety
disorder, for whom the latter would clinically be the
target condition of treatment. We reasoned such
cases should be excluded from our trial.
3) We allowed more flexible titration schedules for step
I. In the original protocol there was only one
anticipated titration schedule for the sertraline 100
mg/day arm, namely 50 mg/day at week 1 titrated
up to 100 mg/day at week 2. In the revised protocol,
any duration of any dosage was permitted at week 1,
such as 75 mg/day for a week or 50 mg/day for 3
days plus 75 mg/day for 4 days, with the minimum
requirement of reaching 100 mg/day at week 2.
4) We also accepted 7.5 mg/day of mirtazapine in step
II. In the original protocol, mirtazapine was to be
prescribed at a dosage of between 15 and 45 mg/
day.
5) A number of new reporting forms were prepared
and updated to gather the necessary information
more systematically and more efficiently.
Discussion
We started the first large-scale pragmatic clinical trial of
antidepressant treatment in Japan in December 2011. This
trial is an assessor-blinded, parallel-group, multi-centre trial
that aims to enrol 2,000 patients with heretofore untreated
unipolar major depressive episodes to determine the
optimum first- and second-line antidepressant treatment
strategies. The current study reports on the feasibility and
adherence of the study protocol and operational procedures
among the first 100 patients.
Patient enrolment and characteristics
At the 12 psychiatric clinics and hospitals associated with
two centres in Nagoya and Kochi, we screened approxi-
mately 2,700 first-visit patients, of whom approximately
400 were judged as possibly being eligible and 100 were fi-
nally entered in the study after providing written informed
consent over the course of the initial 8 months of the
study. We consider that this is a respectable figure and
calculate that, if we can liaise with six more centres, each
associated with five clinics or hospitals in the main study,
we would be able to enrol eight centres * 6 patients/month
* 36 months= approximately 1,800 patients in 3 years.
If we can continue with the one out of four recruitment
rate and the sample characteristics as shown in Tables 2 and
3, we can be confident that our cohort will be representative
of mildly to very severely depressed patients seeking initial
treatment for their untreated depressive episodes. Forexample, the female:male ratio of 56:44=1.3, though much
lower than the 2:1 ratio usually observed in American or
European samples, is close to the ratio of 1.4 reported in a
former Japanese study of a similar inception cohort of un-
treated major depression [13].Randomisation
The randomisation for step I was balanced at the level of
clinics and hospitals between 50 mg/day and 100 mg/day
arms, but was unbalanced at the individual level because of
one very actively recruiting clinic. While this imbalance in the
numbers of patients allocated to the two arms may slightly
decrease the statistical power, it is unlikely to undermine the
internal validity of step I. Moreover, we expect that the treat-
ment allocation will eventually be balanced as we enrol more
participating centres and clinics in the main study.
The randomisation for step II was well balanced among
its three arms and its strata.Treatment adherence
In step I, of the 93 patients who should have reached the
end of this step, nine (9.7%) withdrew their consent to the
protocol treatment. Of the remaining 84 patients, 74
(88.1%) received the treatments as required by the protocol.
In step II, of the 62 patients who had been randomised
to one of the three treatment arms and who should have
reached the end of this step, only three (4.8%) withdrew
consent to the protocol treatments. When the patients
continued to receive treatment in any one of the three
arms, no protocol deviation occurred.
A voluntary withdrawal rate from the assigned treat-
ment of between 5-10% and a protocol deviation rate of
between 0-10% if continued would be acceptable figures
in a large pragmatic trial [14,15].Follow-up assessments
In the study protocol we sharply distinguished between
withdrawal from the protocol treatments and that from
the follow-up assessments, and invited the patients to
cooperate with the follow-up assessments even if they
had voluntarily chosen to withdraw from the assigned
treatments. As a result, we have so far been able to suc-
cessfully assess 96.8%, 97.2% and 90.6% of the intention-
to-treat sample at week 3, 9 and 25, respectively. We
accept that the follow-up rate at week 25 needs to be
improved.
In this study we were able to establish the inter- and
intra-rater (test-retest) reliability of our primary outcomes
and also to ascertain the successful blinding of the assess-
ments thus made. This trial therefore represents one of the
fewer instances where blinding was appropriately tested
and confirmed [16].
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We encountered no unexpected or concerning safety issues
among our first 100 patients.
Conclusion
Based on the present feasibility and adherence examina-
tions of the pilot study phase of the SUN(^_^)D study, we
conclude that the study protocol [3] can be implemented
as originally envisaged with some minor modifications only
and that the data from the first 100 patients can therefore
be safely and validly included towards the main study. We
will continue with the pilot phase of the study as we had
originally set out in the protocol until the first 200 patients
have completed their 25-week follow-ups, but we are now
confident that we can speed up recruitment of collaborat-
ing centres and clinics/hospitals, thereby accelerating not
only the pilot phase but also the entire study itself.
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